Haemonetics Corporation

HAE · NYSE · ·

Karşılaştır

$122,71+%1,912 Kas kapanış

26 Eylül 2026 tarihine kadarki rakamlar, 5 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: +%2,3
1M: +%1,3

Just reported

Q2 FY2027 results

From Haemonetics's results release of 5 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$357,8M
+%9,3 y/y
+%5,4 q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1,00
+%23 y/y
+%39 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$75,1M
+%28 y/y
+%31 q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Haemonetics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Haemonetics Corporation şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Haemonetics Corporation

Haemonetics Corporation

Q2 FY2027 results

Revenue

EPS, GAAP

Operating income, GAAP

Keep exploring

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Q2 FY2027 results

Revenue

EPS, GAAP

Operating income, GAAP

Keep exploring

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Büyüme ve nakit — 5 üzerinden 5

İş eğilimi

Zaman içinde hisse fiyatı ve not